Edwards Lifesciences Corporation (EW) reported adjusted earnings per share (EPS) of 70 cents in the second quarter of 2024, in line with the Zacks Consensus Estimate. The figure also increased 6.1% from the year-ago quarter’s level.The company’s previously announced sale of Critical Care for $4.2 billion remains on track and is expected to close in the late third quarter of 2024. The unit is now presented as discontinued operations.On this note, GAAP EPS from continuing operations was 61 cents in the second ...